과제정보
This research was supported by Seoul National University Bundang Hospital Research Fund (14-2014-037). Yoo-Seok Yoon received a research grant from Seoul National University Bundang Hospital.
참고문헌
- Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013;24:2484-2492 https://doi.org/10.1093/annonc/mdt239
- Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, et al. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol 2014;21:1530-1537 https://doi.org/10.1245/s10434-014-3486-z
- Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833-846; discussion 846-848 https://doi.org/10.1016/j.jamcollsurg.2007.12.020
- National Comprehensive Cancer Network. Pancreatic adenocarcinoma (Version 1.2021). Tri-kobe.org Web site. https://www2.tri-kobe.org/nccn/guideline/pancreas/english/pancreatic.pdf. Published October 23, 2020. Accessed August 23, 2021
- Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 2017;35:515-522 https://doi.org/10.1200/JCO.2016.68.5081
- Blair AB, Sorber R, Rozich NS, Burkhart RA. A qualitative review of neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma. Pancreas 2019;48:973-984 https://doi.org/10.1097/MPA.0000000000001376
- Tamburrino D, Riviere D, Yaghoobi M, Davidson BR, Gurusamy KS. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2016;9:CD011515
- Royal College of Pathologists. Standards and minimum datasets for reporting cancers. Minimum dataset for the histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma. London: Royal College of Pathologists, 2002
- Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008;15:1651-1660 https://doi.org/10.1245/s10434-008-9839-8
- Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel) 2010;2:2001-2010 https://doi.org/10.3390/cancers2042001
- Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford) 2009;11:282-289 https://doi.org/10.1111/j.1477-2574.2009.00055.x
- Weyhe D, Obonyo D, Uslar VN, Stricker I, Tannapfel A. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: making a case for standardized reporting of the resection margin using certified cancer center data. PLoS One 2021;16:e0248633
- Rau BM, Moritz K, Schuschan S, Alsfasser G, Prall F, Klar E. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Surgery 2012;152:S103-S111 https://doi.org/10.1016/j.surg.2012.05.015
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 2015;277:826-832 https://doi.org/10.1148/radiol.2015151516
- Verbeke CS. Resection margins and R1 rates in pancreatic cancer--are we there yet? Histopathology 2008;52:787-796 https://doi.org/10.1111/j.1365-2559.2007.02935.x
- Mochizuki K, Gabata T, Kozaka K, Hattori Y, Zen Y, Kitagawa H, et al. MDCT findings of extrapancreatic nerve plexus invasion by pancreas head carcinoma: correlation with en bloc pathological specimens and diagnostic accuracy. Eur Radiol 2010;20:1757-1767 https://doi.org/10.1007/s00330-010-1727-5
- Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 2009;55:277-283 https://doi.org/10.1111/j.1365-2559.2009.03376.x
- American Joint Committee on Cancer. AJCC cancer staging manual, 8th ed. New York: Springer International Publishing, 2017
- Joo I, Lee JM, Lee ES, Son JY, Lee DH, Ahn SJ, et al. Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement. Radiology 2019;293:343-349 https://doi.org/10.1148/radiol.2019190422
- Hong SB, Lee SS, Kim JH, Kim HJ, Byun JH, Hong SM, et al. Pancreatic cancer CT: prediction of resectability according to NCCN criteria. Radiology 2018;289:710-718 https://doi.org/10.1148/radiol.2018180628
- Deshmukh SD, Willmann JK, Jeffrey RB. Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol 2010;194:668-674 https://doi.org/10.2214/AJR.09.3285
- Sai M, Mori H, Kiyonaga M, Kosen K, Yamada Y, Matsumoto S. Peripancreatic lymphatic invasion by pancreatic carcinoma: evaluation with multi-detector row CT. Abdom Imaging 2010;35:154-162 https://doi.org/10.1007/s00261-008-9461-z
- Verbeke CS, Knapp J, Gladhaug IP. Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology 2011;59:1111-1121 https://doi.org/10.1111/j.1365-2559.2011.04056.x
- Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-Kenudson M, et al. Does size matter in pancreatic cancer? Reappraisal of tumour dimension as a predictor of outcome beyond the TNM. Ann Surg 2017;266:142-148 https://doi.org/10.1097/SLA.0000000000001837
- Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2011;80:1383-1390 https://doi.org/10.1016/j.ijrobp.2010.04.058
- Inoue Y, Saiura A, Oba A, Kawakatsu S, Ono Y, Sato T, et al. Optimal extent of superior mesenteric artery dissection during pancreaticoduodenectomy for pancreatic cancer: balancing surgical and oncological safety. J Gastrointest Surg 2019;23:1373-1383 https://doi.org/10.1007/s11605-018-3995-3
- Okano K, Suto H, Oshima M, Maeda E, Yamamoto N, Kakinoki K, et al. A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 2017;24:2777-2784 https://doi.org/10.1245/s10434-017-5921-4
- Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol 2014;113:41-46 https://doi.org/10.1016/j.radonc.2014.09.010
- Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011;11:346
- Labori KJ, Lassen K, Hoem D, Gronbech JE, Soreide JA, Mortensen K, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg 2017;17:94
- Chawla A, Roland C, Ferrone C. ALLIANCE A021806 examines perioperative vs. adjuvant chemotherapy for resectable pancreatic cancer. In: American College of Surgeons, ed. The bulletin of the American College of Surgeons. Chicago: American College of Surgeons, 2020:40-43